MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Study of Open Label Losartan in COVID-19

Phase 1
Completed
Conditions
COVID-19
Interventions
First Posted Date
2020-04-06
Last Posted Date
2024-08-02
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
34
Registration Number
NCT04335123
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19

Phase 2
Terminated
Conditions
SARS-CoV-2 Infection
Interventions
Drug: Placebo
First Posted Date
2020-03-31
Last Posted Date
2022-03-24
Lead Sponsor
Bassett Healthcare
Target Recruit Count
15
Registration Number
NCT04328012
Locations
🇺🇸

Bassett Medical Center, Cooperstown, New York, United States

A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2020-03-26
Last Posted Date
2020-03-26
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
61
Registration Number
NCT04322266
Locations
🇰🇷

Korea University Hospital (Anam), Seoul, Korea, Republic of

Losartan for Patients With COVID-19 Requiring Hospitalization

Phase 2
Completed
Conditions
Acute Respiratory Distress Syndrome
SARS-CoV Infection
Corona Virus Infection
Interventions
Other: Placebo
First Posted Date
2020-03-17
Last Posted Date
2022-06-29
Lead Sponsor
University of Minnesota
Target Recruit Count
205
Registration Number
NCT04312009
Locations
🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

🇺🇸

Hennepin County Medical Center, Minneapolis, Minnesota, United States

🇺🇸

M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States

and more 10 locations

Losartan for Patients With COVID-19 Not Requiring Hospitalization

Phase 2
Completed
Conditions
Acute Respiratory Distress Syndrome
SARS-CoV Infection
Corona Virus Infection
Interventions
Other: Placebo
First Posted Date
2020-03-17
Last Posted Date
2022-05-04
Lead Sponsor
University of Minnesota
Target Recruit Count
117
Registration Number
NCT04311177
Locations
🇺🇸

Mayo Clinic Health System, Rochester, Minnesota, United States

🇺🇸

Hennepin County Medical Center, Minneapolis, Minnesota, United States

🇺🇸

M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States

and more 1 locations

The Effect of Losartan on the Recoverability of Renal Function in Anuric and Oliguric Patients With Unilateral Obstructed Kidney

Not Applicable
Completed
Conditions
Losartan Adverse Reaction
Uropathy
Uropathy Obstructive
Interventions
First Posted Date
2020-02-20
Last Posted Date
2020-02-20
Lead Sponsor
Mansoura University
Target Recruit Count
96
Registration Number
NCT04278495
Locations
🇪🇬

Urology and nephrology center, Mansoura, Outside U.S./Canada, Egypt

Renohemodynamic Effects of Combined empagliflOzin and LosARtan

Phase 4
Completed
Conditions
Diabetic Kidney Disease
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2020-01-23
Last Posted Date
2021-10-08
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
24
Registration Number
NCT04238702
Locations
🇳🇱

VU University Medical Center, Amsterdam, Noord-Holland, Netherlands

Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients

Phase 4
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
First Posted Date
2020-01-10
Last Posted Date
2020-01-10
Lead Sponsor
Yaounde Central Hospital
Target Recruit Count
23
Registration Number
NCT04222686
Locations
🇨🇲

Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon

Losartan to Improve Hip Microfracture

Phase 1
Terminated
Conditions
Hip Impingement Syndrome
Fibrosis
Hip Osteoarthritis
Cartilage Damage
Interventions
Other: Placebo
First Posted Date
2019-12-27
Last Posted Date
2023-10-30
Lead Sponsor
Steadman Philippon Research Institute
Target Recruit Count
1
Registration Number
NCT04212650
Locations
🇺🇸

Steadman Philippon Research Institute, Vail, Colorado, United States

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)

Phase 1
Active, not recruiting
Conditions
Borderline Resectable Pancreatic Adenocarcinoma
Locally Advanced Unresectable Pancreatic Adenocarcinoma
Stage II Pancreatic Cancer AJCC v8
Stage IIA Pancreatic Cancer AJCC v8
Stage IIB Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Radiation: Hypofractionated Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2019-09-27
Last Posted Date
2025-04-06
Lead Sponsor
University of Utah
Target Recruit Count
22
Registration Number
NCT04106856
Locations
🇺🇸

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath